In a extensive meta-analysis of data from 12 clinical trials over nine years and 4,902 patients, researchers at the Division of Clinical Decision Making, Informatics and Telemedicine at Tufts Medical Center distilled the common thread of findings comparing drug-eluting with bare metal stents. The conclusion, succinctly, is:
"Coronary drug-eluting stents significantly reduced the rates of restenosis and the need for repeat revascularization compared with bare-metal stents."
This finding was represented in the constituent studies, published previously, so it is no revelation. Also included in the findings, however, is the clear indication that drug-eluting stents are expensive, and it is only their ability to preempt the need for repeat vascularizations that warrants their use.
Data indicates that pricing trends correlate with the pressure on cost. The development of more advanced options for anti-restenosis, including bioabsorbable stents, reflects the drive for even better outcomes (reduced risks associated with long-term implantation) and the incentive for manufacturers to gain new market advantage.
See Report #C245, "Worldwide Market for Drug-Eluting, Bare Metal and Other Coronary Stents, 2008-2017."